Viridian Therapeutics, Inc. VRDN 深 沪
交易中 10-01 12:07:35 美东时间
19.32
-1.270
-6.17%
华盛通- 最 高20.58
- 今 开20.54
- 成交量 76.98万股
- 最 低 19.17
- 昨 收 20.59
- 总市值 21.89亿
- 52周最高 34.29
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 13.18
- 委 比 -47.19%
- 总股本 1.13亿
- 历史最高 270.00
- 量 比 1.28
- 振 幅 6.85%
- 历史最低 4.665
- 每 手 1
- 风险率 6.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.
09-22 21:32
Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI
In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a ...
08-10 20:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Viridian Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results.
Viridian Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results.
08-07 03:50
财报速睇 | Viridian Therapeutics, Inc. 2026财年Q2营收0.00亿美元，同比增长278.7%；归母净利润亏损1.13亿美元，同比亏损扩大37.6%
华盛资讯8月6日讯，Viridian Therapeutics, Inc.公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长278.7%，归母净利润亏损1.13亿美元，同比亏损扩大37.6%。
08-06 20:18
Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 5 percent decrease over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $233.000 th...
08-06 19:50
财报速睇 | Viridian Therapeutics, Inc. 2026财年Q2营收0.00亿美元，同比增长278.7%；归母净利润亏损1.27亿美元，同比亏损扩大26.2%
华盛资讯8月6日讯，Viridian Therapeutics, Inc.公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长278.7%，归母净利润亏损1.27亿美元，同比亏损扩大26.2%。
08-06 19:49
美股夜盘 | Penguin Solutions Incorporation涨6.30%，京东涨3.28%
Penguin Solutions Incorporation涨6.30%；京东涨3.28%；MACOM Technology Solutions涨3.10%
07-08 10:01
美股夜盘 | Penguin Solutions Incorporation涨5.96%，闪迪涨4.37%
Penguin Solutions Incorporation涨5.96%；闪迪涨4.37%；Astera Labs涨3.52%
07-08 09:01
